At a manufacturing hub in Meadowbrook, south of Brisbane, four high-security vaults are lined with boxes and bottles of cannabis, MDMA and psilocybin capsules.
They were made earlier on the same site in specialised, purpose-built rooms where raw active ingredients are transformed into patient-ready dosage forms, such as tablets of different strengths. Conveyor belts of pills are packaged into white bottles and labelled.
The factory, operated by ASX-listed BLS Pharmaceuticals, produces pharmaceutical-grade medicines to be sold to clinics around Australia and exported to Germany, the United Kingdom and elsewhere, where they are administered to patients with mental health disorders such as treatment-resistant depression and post-traumatic stress disorder.
These are not your usual pharmaceutical products. Their psychedelic – or mind-altering – properties mean they are strictly regulated, and their distribution is limited to a handful of trained psychiatrists.
A decade ago, those products would have been sold only on the black market as party drugs.
The BLS manufacturing hub is evidence of the growing acceptance of mind-altering therapies, which supporters argue are the key to tackling a growing mental health crisis when traditional treatments often fail.
MDMA – better known as ecstasy – and psilocybin – a psychedelic compound found in some mushrooms – are also becoming big business.
The sector has the potential to become a big manufacturing opportunity for Australia, says BLS chief executive Sam Watson, who developed the company out of a health supplements brand called Dr Watson he founded in his 20s. Now it has a market capitalisation of $214 million and has operations in Australia, the UK, Japan and Europe, and employs 129 staff.
“The power of these medicines is amazing,” says Watson. “I have had limited but very powerful and meaningful experiences with these things.
“Now the tide is changing and all of a sudden, governments are saying this works. Australia has big potential to be a global supplier.”
Read the full article by the Australian Financial Review: https://www.afr.com/companies/healthcare-and-fitness/black-market-to-biotech-inside-australia-s-legal-psychedelic-factory-20260526-p600ty